13,410
edits
m
Deprecated parameter removal from Template:infobox scientist
m (robot: Update article (please report if you notice any mistake or error in this edit)) |
m (Deprecated parameter removal from Template:infobox scientist) |
||
| Line 1: | Line 1: | ||
{{Use dmy dates|date=February 2020}} | {{Use dmy dates|date=February 2020}} | ||
{{Infobox scientist | {{Infobox scientist | ||
| name = Dipyaman Ganguly | | name = Dipyaman Ganguly | ||
| image = | | image = | ||
| alt = | | alt = | ||
| caption = | | caption = | ||
| birth_date = 25 October | | birth_date = 25 October | ||
| birth_place = [[Baharampur]], [[West Bengal]], India | | birth_place = [[Baharampur]], [[West Bengal]], India | ||
| death_date = | | death_date = | ||
| death_place = | | death_place = | ||
| nationality = [[Indian nationality|Indian]] | |||
| nationality = [[Indian nationality|Indian]] | | fields = {{ublist| [[Immunology]] | [[Cell biology]] |}} | ||
| fields = {{ublist| [[Immunology]] | [[Cell biology]] |}} | | workplaces = {{ublist | [[Indian Institute of Chemical Biology]] }} | ||
| workplaces = {{ublist | [[Indian Institute of Chemical Biology]] }} | | alma_mater = {{ublist|[[Rahara Ramakrishna Mission Boys' Home High School|Rahara Ramakrishna Mission Boys’ Home High School]]|[[Medical College and Hospital, Kolkata]] |[[Indian Institute of Chemical Biology]] | [[University of Texas MD Anderson Cancer Center]] | [[Columbia University Medical Center]] }} | ||
| alma_mater = {{ublist|[[Rahara Ramakrishna Mission Boys' Home High School|Rahara Ramakrishna Mission Boys’ Home High School]]|[[Medical College and Hospital, Kolkata]] |[[Indian Institute of Chemical Biology]] | [[University of Texas MD Anderson Cancer Center]] | [[Columbia University Medical Center]] }} | | doctoral_advisor = | ||
| doctoral_advisor = | |||
| doctoral_students = | | doctoral_students = | ||
| known_for = Studies on [[Immunology|Human Immunology]] | | known_for = Studies on [[Immunology|Human Immunology]] | ||
| awards = {{ublist| 2013 [[Ramanujan Fellowship]] |2017 [[Swarnajayanti Fellowship]] | 2017 [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award | 2017/18 [[National Bioscience Award for Career Development|N-BIOS Prize]] | 2019 [[CDRI Award for Excellence in Drug Research]]| 2019 [[Merck Young Scientist Award]] }} | | awards = {{ublist| 2013 [[Ramanujan Fellowship]] |2017 [[Swarnajayanti Fellowship]] | 2017 [[National Academy of Sciences, India|NASI]]-Scopus Young Scientist Award | 2017/18 [[National Bioscience Award for Career Development|N-BIOS Prize]] | 2019 [[CDRI Award for Excellence in Drug Research]]| 2019 [[Merck Young Scientist Award]] }} | ||
}} | }} | ||
'''Dipyaman Ganguly''' is an Indian physician-scientist [[immunologist]] and [[cell biologist]], currently a Principal Scientist and Swarnajayanthi Fellow at the CSIR-[[Indian Institute of Chemical Biology]] (IICB).<ref name="Profile on SERB">{{Cite web |url=http://www.serb.gov.in/pdfs/ramanujan2014/Dipyaman-Ganguly.pdf |title=Profile on SERB |date=2018-12-27 |website=Scientific and Engineering Research Board |access-date=2018-12-27}}</ref> He heads the Dendritic Cell Laboratory of IICB, popularly known as Ganguly Lab, where he hosts several researchers involved in research on regulation of innate Immunity and pathogenesis of [[inflammatory disorders]].<ref name="DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab">{{Cite web |url=https://sites.google.com/site/dclabiicb/dclab-team |title=DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab |date=2018-12-27 |website=sites.google.com |access-date=2018-12-27}}</ref> | '''Dipyaman Ganguly''' is an Indian physician-scientist [[immunologist]] and [[cell biologist]], currently a Principal Scientist and Swarnajayanthi Fellow at the CSIR-[[Indian Institute of Chemical Biology]] (IICB).<ref name="Profile on SERB">{{Cite web |url=http://www.serb.gov.in/pdfs/ramanujan2014/Dipyaman-Ganguly.pdf |title=Profile on SERB |date=2018-12-27 |website=Scientific and Engineering Research Board |access-date=2018-12-27}}</ref> He heads the Dendritic Cell Laboratory of IICB, popularly known as Ganguly Lab, where he hosts several researchers involved in research on regulation of innate Immunity and pathogenesis of [[inflammatory disorders]].<ref name="DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab">{{Cite web |url=https://sites.google.com/site/dclabiicb/dclab-team |title=DC Lab Team - Dendritic Cell Biology Laboratory @ IICB Ganguly Lab |date=2018-12-27 |website=sites.google.com |access-date=2018-12-27}}</ref> | ||
| Line 24: | Line 23: | ||
== Scientific contribution == | == Scientific contribution == | ||
Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.<ref>{{Cite journal|last1=Liu|first1=Chinky Shiu Chen|last2=Raychaudhuri|first2=Deblina|last3=Paul|first3=Barnali|last4=Chakrabarty|first4=Yogaditya|last5=Ghosh|first5=Amrit Raj|last6=Rahaman|first6=Oindrila|last7=Talukdar|first7=Arindam|last8=Ganguly|first8=Dipyaman|date=2018-02-15|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation|journal=The Journal of Immunology|language=en|volume=200|issue=4|pages=1255–1260|doi=10.4049/jimmunol.1701118|pmid=29330322|issn=0022-1767|doi-access=free}}</ref> They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.<ref>{{Cite web|url=https://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/|title=Why the obese are prone to diabetes: a protein gives a clue|date=2016-09-26|website=The Indian Express|language=en-IN|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/india/obesity-link-to-diabetes-decoded/cid/1517526|title=Obesity link to diabetes decoded|website=www.telegraphindia.com|language=en|access-date=2019-07-10}}</ref> Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,<ref>{{Cite journal|last1=Ganguly|first1=Dipyaman|last2=Chamilos|first2=Georgios|last3=Lande|first3=Roberto|last4=Gregorio|first4=Josh|last5=Meller|first5=Stephan|last6=Facchinetti|first6=Valeria|last7=Homey|first7=Bernhard|last8=Barrat|first8=Franck J.|last9=Zal|first9=Tomasz|date=2009-08-31|title=Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|language=en|volume=206|issue=9|pages=1983–1994|doi=10.1084/jem.20090480|pmid=19703986|issn=0022-1007|pmc=2737167}}</ref> as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,<ref>{{Cite journal|last=Bosch|first=Xavier|date=2011-08-25|title=Systemic Lupus Erythematosus and the Neutrophil|journal=New England Journal of Medicine|language=en|volume=365|issue=8|pages=758–760|doi=10.1056/NEJMcibr1107085|pmid=21864171|issn=0028-4793}}</ref> which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.<ref>{{Cite web|url=https://biotechtimes.org/2018/06/03/iicb-scientists-aiming-first-class-drugs-autoimmune-diseases/|title=IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases|date=2018-06-03|website=BioTech Times|language=en-US|access-date=2019-07-10}}</ref> Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.<ref>{{Cite | Research interests of Ganguly lab are exploring the role of dendritic cells in autoreactive inflammatory contexts, deciphering molecular regulation of innate immune response and exploring the role of mechanical cues in immune cells. Researchers from Ganguly Lab recently discovered a novel regulatory module involving the Piezo1 mechanosensors in human T cells, driven by mechanical cues.<ref>{{Cite journal|last1=Liu|first1=Chinky Shiu Chen|last2=Raychaudhuri|first2=Deblina|last3=Paul|first3=Barnali|last4=Chakrabarty|first4=Yogaditya|last5=Ghosh|first5=Amrit Raj|last6=Rahaman|first6=Oindrila|last7=Talukdar|first7=Arindam|last8=Ganguly|first8=Dipyaman|date=2018-02-15|title=Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation|journal=The Journal of Immunology|language=en|volume=200|issue=4|pages=1255–1260|doi=10.4049/jimmunol.1701118|pmid=29330322|issn=0022-1767|doi-access=free}}</ref> They also provided the first evidence for involvement of plasmacytoid dendritic cells in obesity and associated metabolic syndrome in humans.<ref>{{Cite web|url=https://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/|title=Why the obese are prone to diabetes: a protein gives a clue|date=2016-09-26|website=The Indian Express|language=en-IN|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/india/obesity-link-to-diabetes-decoded/cid/1517526|title=Obesity link to diabetes decoded|website=www.telegraphindia.com|language=en|access-date=2019-07-10}}</ref> Previous work by Dipyaman Ganguly led to discovery of the key initiation events in pathogenesis of the skin autoimmunity in Psoriasis,<ref>{{Cite journal|last1=Ganguly|first1=Dipyaman|last2=Chamilos|first2=Georgios|last3=Lande|first3=Roberto|last4=Gregorio|first4=Josh|last5=Meller|first5=Stephan|last6=Facchinetti|first6=Valeria|last7=Homey|first7=Bernhard|last8=Barrat|first8=Franck J.|last9=Zal|first9=Tomasz|date=2009-08-31|title=Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|language=en|volume=206|issue=9|pages=1983–1994|doi=10.1084/jem.20090480|pmid=19703986|issn=0022-1007|pmc=2737167}}</ref> as well as first identification of dying neutrophils as the major source of nuclear antigens in systemic lupus,<ref>{{Cite journal|last=Bosch|first=Xavier|date=2011-08-25|title=Systemic Lupus Erythematosus and the Neutrophil|journal=New England Journal of Medicine|language=en|volume=365|issue=8|pages=758–760|doi=10.1056/NEJMcibr1107085|pmid=21864171|issn=0028-4793}}</ref> which was featured in Nature Reviews Key Advances in Medicine for the year 2012. Ganguly lab has also interest in development of new therapies for autoimmune diseases.<ref>{{Cite web|url=https://biotechtimes.org/2018/06/03/iicb-scientists-aiming-first-class-drugs-autoimmune-diseases/|title=IICB Scientists Aiming at First-in-Class Drugs for Autoimmune Diseases|date=2018-06-03|website=BioTech Times|language=en-US|access-date=2019-07-10}}</ref> Ganguly lab also took interest in performing research on immunology of COVID-19 disease and ran a randomized control trial on convalescent plasma therapy.<ref>{{Cite journal|url=https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1/|title=Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomized control trial|year=2020|doi=10.1101/2020.11.25.20237883|last1=Ray|first1=Yogiraj|last2=Paul|first2=Shekhar Ranjan|last3=Bandopadhyay|first3=Purbita|last4=d'Rozario|first4=Ranit|last5=Sarif|first5=Jafar|last6=Lahiri|first6=Abhishake|last7=Bhowmik|first7=Debaleena|last8=Vasudevan|first8=Janani Srinivasa|last9=Maurya|first9=Ranjeet|last10=Kanakan|first10=Akshay|last11=Sharma|first11=Sachin|last12=Kumar|first12=Manish|last13=Singh|first13=Praveen|last14=Roy|first14=Rammohan|last15=Chaudhury|first15=Kausik|last16=Maiti|first16=Rajsekhar|last17=Bagchi|first17=Saugata|last18=Maiti|first18=Ayan|last19=Perwez|first19=Md. Masoom|last20=Mondal|first20=Abhinandan|last21=Tewari|first21=Avinash|last22=Mandal|first22=Samik|last23=Roy|first23=Arpan|last24=Saha|first24=Moumita|last25=Biswas|first25=Durba|last26=Maiti|first26=Chikam|last27=Chakraborty|first27=Sayantan|last28=Sarkar|first28=Biswanath Sharma|last29=Haldar|first29=Anima|last30=Saha|first30=Bibhuti|s2cid=227189790|display-authors=1}}</ref> | ||
== Awards == | == Awards == | ||
| Line 30: | Line 29: | ||
== Public outreach == | == Public outreach == | ||
Ganguly is an enthusiast for public outreach of science in India,<ref>{{Cite web|url=http://dialogue.ias.ac.in/|title=DIALOGUE - Science, Scientists, and Society|website=Dialogue|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://indiabioscience.org/columns/conversations/are-we-reaching-the-public-with-our-public-outreach-programs|title=Are we reaching the 'public' with our public outreach programs?|date=2018-07-13|website=IndiaBioscience|access-date=2019-07-10}}</ref> an avid stargazer and a public commentator and popular columnist on issues on science and health. <ref>{{Cite web|url=https://www.telegraphindia.com/west-bengal/calcutta/coronavirus-the-fight-the-soldiers/cid/1765874|title=Coronavirus: the fight & the soldiers}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/coronavirus-pandemic-preparing-for-long-lasting-covid/cid/1797372|title=Preparing for long-lasting Covid}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/one-pandemic-unmasking-another/cid/1800550|title=One pandemic unmasking another}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/will-the-vaccines-protect-us-from-new-strains-of-the-novel-coronavirus/cid/1804558|title=Will the vaccines protect us from new strains of the novel coronavirus?}}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/more-strain-on-covid-management/article33560841.ece|title=More 'strain' on Covid management}}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/slow-mutation-of-the-covid-pandemic/article33794829.ece|title=Slow mutation of the Covid pandemic}}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2021/apr/21/interview--pandemic-will-end-up-as-an-endemicsays-immunologist-dr-dipyaman-ganguly-2292921.html|title=Pandemic will end up as an endemic}}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2020/jul/25/interview--herd-immunity-may-come-before-covid-19-vaccine-says-dr-dipyaman-ganguly-2174783.html|title=Herd immunity may come before COVID-19 vaccine}}</ref> | Ganguly is an enthusiast for public outreach of science in India,<ref>{{Cite web|url=http://dialogue.ias.ac.in/|title=DIALOGUE - Science, Scientists, and Society|website=Dialogue|access-date=2019-07-10}}</ref><ref>{{Cite web|url=https://indiabioscience.org/columns/conversations/are-we-reaching-the-public-with-our-public-outreach-programs|title=Are we reaching the 'public' with our public outreach programs?|date=2018-07-13|website=IndiaBioscience|access-date=2019-07-10}}</ref> an avid stargazer and a public commentator and popular columnist on issues on science and health.<ref>{{Cite web|url=https://www.telegraphindia.com/west-bengal/calcutta/coronavirus-the-fight-the-soldiers/cid/1765874|title=Coronavirus: the fight & the soldiers}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/coronavirus-pandemic-preparing-for-long-lasting-covid/cid/1797372|title=Preparing for long-lasting Covid}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/one-pandemic-unmasking-another/cid/1800550|title=One pandemic unmasking another}}</ref><ref>{{Cite web|url=https://www.telegraphindia.com/opinion/will-the-vaccines-protect-us-from-new-strains-of-the-novel-coronavirus/cid/1804558|title=Will the vaccines protect us from new strains of the novel coronavirus?}}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/more-strain-on-covid-management/article33560841.ece|title=More 'strain' on Covid management|date=12 January 2021 }}</ref><ref>{{Cite web|url=https://www.thehindubusinessline.com/opinion/slow-mutation-of-the-covid-pandemic/article33794829.ece|title=Slow mutation of the Covid pandemic|date=9 February 2021 }}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2021/apr/21/interview--pandemic-will-end-up-as-an-endemicsays-immunologist-dr-dipyaman-ganguly-2292921.html|title=Pandemic will end up as an endemic}}</ref><ref>{{Cite web|url=https://www.newindianexpress.com/nation/2020/jul/25/interview--herd-immunity-may-come-before-covid-19-vaccine-says-dr-dipyaman-ganguly-2174783.html|title=Herd immunity may come before COVID-19 vaccine}}</ref> | ||
== Selected bibliography == | == Selected bibliography == | ||
| Line 45: | Line 44: | ||
* {{cite journal|vauthors=Ganguly D, Haak S, Sisirak V, Reizis B|title=The role of dendritic cells in autoimmunity|journal=Nature Reviews Immunology|volume=13|pages=566–577|date=Aug 2013|issue=8|pmid=23827956 |doi=10.1038/nri3477|pmc=4160805}} | * {{cite journal|vauthors=Ganguly D, Haak S, Sisirak V, Reizis B|title=The role of dendritic cells in autoimmunity|journal=Nature Reviews Immunology|volume=13|pages=566–577|date=Aug 2013|issue=8|pmid=23827956 |doi=10.1038/nri3477|pmc=4160805}} | ||
* {{cite journal|vauthors=Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M|title=Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|volume=206|pages=1983–1994|date=Aug 2009|issue=9|pmid=19703986 |doi=10.1084/jem.20090480|pmc=2737167|doi-access=free}} | * {{cite journal|vauthors=Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M|title=Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8|journal=The Journal of Experimental Medicine|volume=206|pages=1983–1994|date=Aug 2009|issue=9|pmid=19703986 |doi=10.1084/jem.20090480|pmc=2737167|doi-access=free}} | ||
* {{cite journal|vauthors=Mukherjee A, Raychaudhuri D, Sinha BP, Kundu B, Mitra M, Paul B, Bandopadhyay P, Ganguly D, Talukdar A|title=A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist|journal=Journal of Medicinal Chemistry|volume=63|pages=4776–4789|date=May 2020|issue=9|pmid=32302115 |doi=10.1021/acs.jmedchem.0c00011}} | * {{cite journal|vauthors=Mukherjee A, Raychaudhuri D, Sinha BP, Kundu B, Mitra M, Paul B, Bandopadhyay P, Ganguly D, Talukdar A|title=A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist|journal=Journal of Medicinal Chemistry|volume=63|pages=4776–4789|date=May 2020|issue=9|pmid=32302115 |doi=10.1021/acs.jmedchem.0c00011|s2cid=215809717 }} | ||
{{Refend}} | {{Refend}} | ||
| Line 65: | Line 64: | ||
{{N-BIOS Laureates 2010–2019}} | {{N-BIOS Laureates 2010–2019}} | ||
{{DEFAULTSORT:Ganguly, Dipyaman}} | {{DEFAULTSORT:Ganguly, Dipyaman}} | ||
| Line 79: | Line 76: | ||
[[Category:Indian immunologists]] | [[Category:Indian immunologists]] | ||
[[Category:Living people]] | [[Category:Living people]] | ||
[[Category:Scientists from West Bengal]] | |||